Loading ...
Sorry, an error occurred while loading the content.

Fwd: [NATAP] Infergen+IFN-gamma in Nonresponders: 48 wks results

Expand Messages
  • claudine intexas
    hcv@natap.org wrote: Date: Mon, 22 Nov 2004 17:10:40 EST To: hcv@natap.org, hcvhiv@natap.org, doctors@natap.org, misc@natap.org, europe@natap.org,
    Message 1 of 1 , Nov 22, 2004
      hcv@... wrote: Date: Mon, 22 Nov 2004 17:10:40 EST
      To: hcv@..., hcvhiv@..., doctors@..., misc@...,
      europe@..., industry@...
      From: hcv@...
      Subject: [NATAP] Infergen+IFN-gamma in Nonresponders: 48 wks results

      NATAP - www.natap.org

      IFN Alfacon (Infergen) + IFN-gamma in Nonresponders: 48 week results

      Reported by Jules Levin

      Carroll Leevy reported these pilot study results at AASLD (October 2004). Preclinical studies have demonstrated strong synergistic antiviral and immunomodulatory effects of the combination of IFN alfacon 1 (consensus interferon; Infergen) and IFN-gamma 1b (Actimmune) in preclinical models of HCV.

      Researchers conducted a retrospective analysis of 50 Null Responders to pegylated IFN alfa 2a + ribavirin therapy who were retreated with IFN alfacon 1, 15 mcg SQ daily, and IFN-gamma 1b 50 mcg SQ TIW for 48 weeks.

      All patients had previously received pegylated interferon alfa 2a (Pegasys) and ribavirin for 12 weeks, and did not have at least a 2- log10 drop in HCV RNA. Serum HCV RNA was assessed at weeks 8, 12, 24, and 48 weeks to determine early virologic response and will be assessed at weeks 48 and 72 to determine end of treatment and sustained virologic responses.

      Patients were monitored for constitutional symptoms and bloods were collected for serum chemistries and hematological evaluations.

      This retrospective case series examined the safety and efficacy of re-treating patients who did not respond to peg-IFN-a-2+RBV therapy with a combination of a bio-engineered type 1 IFN (IFN alfacon-1) and a recombinant type 2 IFN (IFN-gamma 1b). IFN-gamma and IFN alfacon-1 display synergistic antiviral activity when combined (Blatt et al AASLD 2003).

      PATIENT CHARACTERISTICS: 26 men; age: 43 yrs; fibrosis stage (Ishak) 0-1: 11 patients, 2-4: 39 patients; HCV genotypes 1 & 4: 45 patients, other 5 patients; weight: mean 79 kg.


      ALT: 51 IU/mL
      AST: 62 IU/mL
      Hemoglobin: 11.5 g/dL
      Platelets: 201,700 mm3
      Serum HCV RNA: 3.27 million copies/ml


      After 8, 12, 24, and 48 weeks treatment, rates of HCV negativity were 36%, 40%, 46%, and 44%, respectively. For genotype 1 patients, the rates of HCV RNA negativity were 36%, 39%, 44%, and 48%, respectively.

      By week 8, all patients hemoglobin levels had returned to normal without the use of EPO, indicating that IFN alfacon & IFN-gamma does not interfere with hemoglobin recovery. By week 24, 11 patients required filgastim for neutropenia.

      Average serum ALT was between 20-30 IU/mL at week 24.

      Patients continue to be treated & assessed. A phase II dose0finding study in nonresponders is underway.

      hcv mailing list

      [Non-text portions of this message have been removed]
    Your message has been successfully submitted and would be delivered to recipients shortly.